SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is actively trending due to proposals around credit card interest rate caps and a significant settlement with merchants over swipe fees. The community is debating whether a rate cap would directly impact Visa's transaction-based revenue model or primarily affect card-issuing banks, while also noting its strategic moves into stablecoin payments.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amidst a sharp debate fueled by a recent analyst downgrade and increased competition in the weight management sector, particularly from Amazon Pharmacy's offering of Novo Nordisk's oral GLP-1 pill. The community is divided, with many expressing concern about the stock's valuation and downside potential, while long-term investors see current price levels as a significant buying opportunity, highlighting the company's expanding healthcare verticals and AI integration.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amid polarized reactions to recent events, with intense community debate surrounding an ICE shooting incident, where some defend law enforcement actions while others decry it as unjustified. Additionally, his public statements about securing oil investments in Venezuela and a potential Greenland acquisition are driving conversations, eliciting both support for his assertive strategies and skepticism regarding their economic and geopolitical implications.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is consistently trending due to its highly active and dedicated community, which is vigorously building a brand ecosystem with real-world products like Kendu Spice and Energy drinks. The community expresses strong conviction, emphasizing continuous development and IRL presence across multiple chains, positioning KENDU as a long-term play with aspirations for significant market cap growth.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending as its community enthusiastically engages with the AirLock initiative, resulting in over 34% of the token supply being locked. This collective control and "Make Holding Great Again" sentiment, coupled with a prominent celebrity's public endorsement and token lock, is driving immense bullish conversation. The community sees AIRCOIN as a revolutionary meme coin on Solana, emphasizing its unique model for transparency and long-term commitment.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending amid fervent community speculation about an impending "infinity short squeeze" following news of the company eliminating convertible debt. However, sharp price volatility and concerns about potential dilution from registered shares fuel an intense debate, with bulls anticipating significant gains fueled by its low float and innovative material tracking technology, while bears predict further declines.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals Inc. ($NBY) is trending with extreme volatility, primarily driven by a special cash dividend and the involvement of investor David Lazar, known for revitalizing distressed companies. The community is sharply divided, actively debating whether it signals a massive short squeeze fueled by low float and high short interest, or an impending pump-and-dump given dilution concerns and prior history. Many are closely analyzing the unique "due bills" dividend procedures and speculating on a potential pivot towards blockchain technology.

Polygon

Polygon is experiencing a surge in bullish sentiment driven by its increasing on-chain revenue and soaring network usage. The community is actively discussing its perceived undervaluation relative to competitors, especially given growing institutional adoption and the impact of token burning on scarcity. Major players leveraging its robust DeFi and payment infrastructure further fuel optimistic expectations.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust (GBTC) is trending amid sharply divided community sentiment on Bitcoin's immediate future, with some anticipating a rapid parabolic ascent fueled by institutional interest and comparisons to gold, while others foresee a prolonged "crypto winter" and significant price corrections. The discussion heavily features debates on historical market cycles, recent ETF inflows and outflows, and concerns about potential market manipulation impacting Bitcoin's valuation.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending due to extended forecasts for unseasonably warm weather, significantly suppressing heating demand and leading to continuous declines in natural gas prices. The community is sharply divided, with some hoping for a polar vortex to spark a reversal, while others caution against the leveraged ETF's historical decay and aggressive downside volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>On Thursday, Sellas said that it received approximately $26.5 million in proceeds from the exercise of common stock warrants.</li><li>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.</li><li>The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) fell for the fourth straight session on Friday as investors resorted to profit taking amid dilution concerns.Shares of the company traded 13% lower at $3.34 at the time of writing, after <a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-breaches-5-dollar-level-after-over-3-years/cmxuTsiR4RS">breaching</a> the $5 threshold for the first time in over three years earlier this week.On Thursday, Sellas said that it received approximately $26.5 million in proceeds from the exercise of common stock warrants. This is in addition to the company’s estimated cash and cash equivalents of $71.8 million as of December-end.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SLS stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user expressed disappointment at the company diluting shares of the company by exercising warrants provided it has “sufficient cash” to carry out ongoing trials. However, they expect the price to be back up by February.<stembedurl>https://www.stocktwits.com/jackobull/message/641370638</stembedurl>Another, however, said that there is no “legitimate reason” to sell the stock. “...we longs know this is short lived. &nbsp;VERY short lived. &nbsp;It will explode upward from this oversold action,” they wrote.<stembedurl>https://www.stocktwits.com/Wut_About_Bob/message/641368167</stembedurl><h2 class="st-heading-2"> What Drove The Recent Rally?</h2>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy. AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding.The ongoing GPS trial is an overall survival study, and final analysis is expected once 80 deaths have occurred. As of December 26, 72 deaths have occurred, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-group-stock-soars-as-it-nears-final-analysis-in-cancer-study/cL7dROARExt">said</a> last month, highlighting that it had previously expected 80 patient deaths to occur by December end.“While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results,” SELLAS CEO Angelos Stergiou said at the time. The announcement kickstarted a rally that mostly sustained through late December and early January.Last week, Maxim analyst Jason McCarthy noted that delays in an event-driven trial like SELLAS’ could be suggestive of extended survival benefit from GPS.Besides GPS, SELLAS has another experimental drug in its pipeline called SLS009 also being developed to target certain cancers.According to data from Koyfin, all three of the analysts covering SELLAS rate it ‘Buy’ or higher. The stock has an average price target of $6.83, hinting at significant potential upside.<a href="https://stocktwits.com/symbol/SLS">SLS shares</a> have nearly tripled over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/kalvista-pharmaceuticals-stock-rallies-after-hours-on-strong-genetic-disorder-drug-sales-kickstart/cmUbnxGR45Z">KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off?

Shares of the company traded 13% lower at $3.34 at the time of writing.

Equity

Shares of the company traded 13% lower at $3.34 at the time of writing.


SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 8.4% - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 8.4% - Here's Why...

<ul class="summary-bullets"><li>Headlines from CES reignited enthusiasm around AI hardware and autonomous tech.</li><li>Despite the dip, retail sentiment on Stocktwits toward SPY and QQQ remained bullish.&nbsp;</li></ul>U.S. stock futures were trading in the red early Tuesday as investors balance AI optimism from CES, while awaiting crucial jobs data later this week.As of 3:50 a.m. ET on Tuesday, Nasdaq 100 futures and S&amp;P 500 futures fell 0.1%, and the Dow futures fell 0.2%, while Russell 2000 futures fell 0.4%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bullish’, amid normal message volumes.Trending Stocks To Watch Nvidia (NVDA):&nbsp;At CES, Jensen Huang&nbsp;announced Nvidia’s next-generation AI chips, Vera Rubin, a successor to&nbsp;its Blackwell architecture, which would go on sale in the second half of the year. It is also joining the push to develop self-driving cars, reinforcing its position as a full-stack AI platform company, not just a chipmaker.&nbsp; Tesla (TSLA): CEO Elon Musk downplayed concerns around Nvidia’s newly unveiled Alpamayo autonomous driving AI.&nbsp; Advanced Micro Devices, Inc. (AMD)&nbsp;garnered retail attention on Stocktwits after the chipmaker&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-crashes-ces-2026-with-all-out-offensive-against-nvidia/cmxwVexR4Tb">launched</a> a slew of AI chips for computers, data centers, and gaming at the CES trade show in Las Vegas. Intel (INTC)&nbsp;unveiled its latest laptop processors, the Core Ultra Series 3, which are set to roll out in new computers later this month. Also, keep an eye on Chevron (CVX), Exxon Mobil Corp (XOM), amid political developments in Venezuela. OneStream (OS):&nbsp;HG Capital is reportedly nearing a deal to acquire the financial software firm.&nbsp; Sellas Lifesciences (SLS)&nbsp;is the top trending ticker on Stocktwits at the time of writing.&nbsp; Aeva (AEVA)&nbsp;is on the retail radar after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tiny-lidar-player-aeva-stock-rockets-over-25-after-hours-on-nvidia-deal/cmxwXUUR4RV">announcing</a> its 4D LiDAR will be integrated into the Nvidia Drive Hyperion platform. PLTR (Palantir) and&nbsp;RCAT (Red Cat Holdings) are trending. Traders are&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/red-cat-roars-back-venezuela-speculation-sends-drone-stock-flying/cmxw13MR4Rs">speculating</a> on increased contract awards for surveillance and drone technology.&nbsp; Zeta Global (ZETA)&nbsp;is gaining traction following the collaboration with OpenAI to enhance its marketing platform. And&nbsp;Alumis (ALMS) is scheduled to report topline Phase 3 data for envudeucitinib in plaque psoriasis before the open, with a conference call at 8:00 a.m. ET.&nbsp; Other noteworthy tickers trending on Stocktwits at the time of writing were Amazon (AMZN), Momentus In (MNTS), Bank of America (BAC), Alibaba (BABA), Paramount Skydance (PSKY), and Apteva Therapeutics (APVO) Other Catalysts To Watch With no significant economic releases due Tuesday, traders are expected to continue tracking CES developments and positioning ahead of key jobs data later this week. Siemens is expected to showcase its Industrial Metaverse, while Lenovo CEO is expected to unveil the “AI for All” strategy today. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data.

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data this week.


<ul class="summary-bullets"><li>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia.</li><li>The stock has had a good run since the company said that slower deaths in the GPS trial might imply further clinical benefit.</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) garnered retail attention on Monday after it breached the $5 threshold after over three years during the day trading session.The stock closed 15% higher in the regular trading session to close at $5 and traded 2% higher after hours.<h2 class="st-heading-2">Retail Speaks</h2>On Stocktwits, retail sentiment around SLS stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘extremely low’ to ‘low’ levels.A bullish Stocktwits user rejoiced at the new levels.<stembedurl>https://www.stocktwits.com/Duncan74/message/640892449</stembedurl>Another expressed optimism for a buyout of the company for as much as $25 billion.<stembedurl>https://www.stocktwits.com/Mjohns92/message/640889738</stembedurl><h2 class="st-heading-2">What’s Driving The Rally?</h2>SELLAS is currently <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-group-stock-soars-as-it-nears-final-analysis-in-cancer-study/cL7dROARExt">evaluating</a> Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy. AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding.The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. As of December 26, 72 deaths have occurred, the company said last month, highlighting that it had previously expected 80 patient deaths to occur by December end.“While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results,” SELLAS CEO Angelos Stergiou then said.Last week, Maxim analyst Jason McCarthy noted that delays in an event-driven trial like SELLAS’ could be suggestive of extended survival benefit from GPS.Besides GPS, SELLAS has another experimental drug in its pipeline called SLS009 also being developed to target certain cancers.According to data from Koyfin, all three of the analysts covering SELLAS rate it ‘Buy’ or higher. The stock has an average price target of $6.83, hinting at further potential upside.<a href="https://stocktwits.com/symbol/SLS">SLS shares</a> have nearly tripled this year and multiplied by about five times in value over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/crnx-stock-gains-nbix-shares-drop-on-positive-results-from-genetics-disorder-trial/cmxMxA1R4Rf">CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

SLS Stock Breaches $5 Level After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B 

SELLAS Life Sciences closed 15% higher in the regular trading session to close at $5 and traded 1% higher after hours.

SLS Stock Breaches $5 Levels After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B 

SELLAS Life Sciences closed 15% higher in the regular trading session to close at $5 and traded 1% higher after hours.


SELLAS Life Sciences Group (NASDAQ:SLS) Sets New 52-Week High - Should You Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 12-Month High - Should You Buy...

Best Penny Stocks To Follow Today - January 4th

Sidus Space, Brand Engagement Network, Ironwood Pharmaceuticals, Datavault AI, SELLAS Life Sciences Group, Lavoro, and TPB Acquisition Co. I are the seven Penny stocks to watch today, according to...

Penny Stocks To Follow Today - January 3rd

SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the recipient of some unusual options trading on Friday. Stock traders purchased 149,934 call options on the stock. This represents...

SELLAS Life Sciences Group (NASDAQ:SLS) Sees Unusually-High Trading Volume - Still a Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Sees Unusually-High Trading Volume - Still a Buy...

Promising Penny Stocks To Add to Your Watchlist - January 1st

Sidus Space, Anghami, Datavault AI, Richtech Robotics, and SELLAS Life Sciences Group are the five Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are shares...

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Stocktwits

Stocktwits Polls

CEO Angelos Stergiou publicly addressed a misleading article, emphasizing the robustness of the science and the positive implications of delayed event thresholds in clinical trials.

Speculation is rife about an impending acquisition or major partnership, with the JPM Healthcare Conference, recent RSU grants, and warrant exercises cited as key indicators.

Recent grants of Restricted Stock Units (RSUs) to executives and board members are interpreted by many as a bullish sign, especially given conditions that accelerate vesting upon a change of control.

Ongoing warrant exercises are creating significant selling pressure and dilution fears, influencing the stock price as shares enter the market.

Despite misinformation, many remain confident in the clinical trial's progress, noting that longer patient survival before reaching the 80-event threshold implies positive efficacy for the treatment.

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SLS News

SLSSELLAS Life Sciences Group Inc